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KEY POINTS 1) The HIF inhibitor acriflavine suppresses TKi-insensitive CML stem cells. 
 
2) The FDA-approved drug acriflavine may represent a novel treatment to prevent 
CML relapse and, in combination with TKi, to improve remission. 
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ABSTRACT 
Chronic myeloid leukemia (CML) is a hematopoietic stem cell (HSC)-driven neoplasia 
characterized by the expression of the constitutively-active tyrosine kinase BCR/Abl. CML therapy 
based on tyrosine kinase inhibitors (TKi) is highly effective in inducing remission but not in 
targeting leukemia stem cells (LSC), which sustain minimal residual disease and are responsible 
for CML relapse following discontinuation of treatment. The identification of molecules capable to 
target LSC appears therefore of primary importance to aim at CML eradication. LSC home in bone 
marrow areas at low oxygen tension where HSC are physiologically hosted. This study addresses 
the effects of the pharmacological inhibition of hypoxia-inducible factor-1 (HIF-1), a critical 
regulator of LSC survival, on the maintenance of CML stem cell potential. 
We found that the HIF-1 inhibitor acriflavine (ACF) decreased survival and growth of CML 
cells. These effects were paralleled by a decreased expression of c-MYC and stemness-related 
genes. Using different in vitro stem cell assays, we showed that ACF, but not TKi, target stem cell 
potential of CML cells, including primary cells explanted from twelve CML patients. Moreover, in a 
murine CML model, ACF decreased leukemia development and reduced LSC maintenance. 
Importantly, ACF exhibited significantly less severe effects on non-CML hematopoietic cells in vitro 
and in vivo. Thus, we propose ACF, an FDA-approved drug for non-oncological use in humans, as 
a novel therapeutic approach to prevent CML relapse and, in combination with TKi, to enhance 
induction of remission.  
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INTRODUCTION 
Chronic myeloid leukemia (CML), a clonal disease affecting hematopoietic stem cells (HSC), is 
driven by the 9;22(q34.1;q11.2) chromosomal translocation, which results in the expression of 
BCR/Abl oncoprotein, a constitutively-active tyrosine kinase. Chronic-phase CML patients are 
treated with tyrosine kinase inhibitors (TKi) targeting BCR/Abl, such as imatinib-mesylate (IM).1 
Successful TKi therapy leads in most cases, rather than to CML cure, to a state of minimal residual 
disease, apparently sustained by the persistence of TKi-resistant leukemia stem cells (LSC).2–6 
Thus, the search for drugs capable of targeting these cells is of primary importance in order to 
eradicate CML. 
In bone marrow (BM), LSC most likely reside in stem cell niches located within tissue areas at 
very low oxygen tension, where HSC are physiologically hosted.7,8 Studies from our group9–11 and 
others12,13 demonstrated that low oxygen maintains HSC survival and stem cell potential, favoring 
HSC self-renewal. The same applies to LSC,14 those of CML in particular.4,5,15 Interestingly, 
BCR/Abl oncoprotein is suppressed in low oxygen.4,5 This mechanism, among others,16,17 well 
explains the refractoriness of LSC to BCR/Abl-targeting TKi, provided they manage to survive in 
the absence of BCR/Abl kinase signaling.  
Hypoxia-inducible factors (HIF) are key regulators of cell adaptation to low oxygen.18  HIF-1 is 
a transcription factor composed of an α and a β subunit and regulated mainly by oxygen tension. 
Oxygen levels lower than 7% stabilize HIF-1α, which binds the HIF-1β subunit and drives the 
transcription of genes regulating energetic metabolism, cell survival/proliferation, and 
angiogenesis.18 HIF-1 also drives cancer progression.19 In CML cell populations, HIF-1α and HIF-
responsive genes are up-regulated by BCR/Abl.20,21 In murine models of CML, the genetic 
knock/out of HIF-1α prevents CML development by impairing cell cycle progression and inducing 
apoptosis in LSC.21 Thus, HIF-1α represents a critical factor in CML and its targeting appears as a 
potential therapeutic strategy to eradicate LSC. 
In this study, we addressed the effects of pharmacological inhibition of HIF-1α in CML. Using 
CML cell lines and primary cells as well as a murine model of CML, we found that LSC that survive 
TKi treatment are instead sensitive to acriflavine (ACF), a HIF-1 inhibitor22 FDA-approved for non-
oncological human use. On this basis, we propose ACF as a novel therapeutic approach to prevent 
CML relapse.  
 
  
For personal use only.on June 28, 2017. by guest  www.bloodjournal.orgFrom 
MATERIALS AND METHODS 
Cells and culture conditions 
Cell lines were cultured in RPMI1640 (K562,23 KCL2224 and LAMA-8425 CML cells) or DMEM 
(HEK293T29 and NIH/3T330 cells) supplemented with 10% FBS, 50 units/ml penicillin, 50 mg/ml 
streptomycin, 2 mM glutamine (Euro-Clone, Paington, U.K.).  
K562 cells transfected with shRNA against HIF-1α (shHIF-1α) or control shRNA against red 
fluorescent protein were sorted on the basis of green fluorescent protein (GFP) expression.26 The 
shRNA sequence targeting HIF-1α was: 
gatgttagctccctatatcccTTCAAGAGAgggatatagggagctaacatc; the control shRNA sequence was: 
gctccaaggtgtacgtgaaTTCAAGAGAttcacgtacaccttggagc (upper case: loop; lower case: shRNA 
sequence). 
Mononuclear cells (MC) from BM (BMMC) of CML patients (Table S1) or peripheral blood (PB; 
buffy coat) of healthy donors were cultured in IMDM supplemented with 20% FBS, 50 units/ml 
penicillin, 50 mg/ml streptomycin, 2 mM glutamine, and cytokines (Supplemental Methods).  
Exponentially-growing cells were plated at 3x105/ml and incubated at 37°C in low oxygen 
(water-saturated atmosphere containing 0.1% O2, 94.9% N2 and 5% CO2) in a DG250 Anaerobic 
Workstation (Don Whitley Scientific, Shipley, Bridgend, U.K.) or normoxia (21% O2 and 5% CO2). 
The O2 concentration used for low-oxygen incubation mimics that of endosteal areas,27,28 in which 
most primitive stem cells reside.7  
Cell viability was measured by trypan blue (#F-7378, Sigma-Aldrich, St. Louis, MO, U.S.A.) 
exclusion test. 
 
Reagents 
3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole (YC-1; #170632-47-0, Sigma-Aldrich), and 
Dasatinib (Dasa; #1586, Biovision, Milpitas, CA, U.S.A.) were dissolved in DMSO. Imatinib (IM; 
#202180, Santa Cruz Biotechnology, Dallas, TX, U.S.A.) and Acriflavine (ACF; #8063-24-9, Sigma-
Aldrich) were dissolved in PBS. ACF decreases HIF transcriptional activity by inhibiting the α/β 
dimerization;22 YC1 inhibits HIF-1α activity by promoting its degradation, inhibiting its translation,31–
33
 stimulating “factor inhibiting HIF” and reducing binding of p300, a co-activator indispensable for 
transcription initiation of HIF-1α-downstream genes.34  
 
Cell lysis and western blotting 
Whole cell lysates were obtained using Laemmli buffer. Hypotonic buffer was used for 
cytosol/nucleus separation. Protein concentration was determined by the BCA method 
(#23225,ThermoFisher Scientific, Waltham, MA, U.S.A.) and 30-50 μg protein/sample were 
subjected to SDS-PAGE and transferred onto PVDF membranes (Merck-Millipore, Billerica, MA, 
U.S.A.) by electroblotting.35 Membranes were incubated overnight at 4°C with primary antibody 
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(Supplemental Methods). Antibodies were diluted 1:1000 or 1:500 (anti-c-Abl, -VEGF -HIF-1α, -
Sox2) in Odyssey Blocking Buffer (OBB; LI-COR® Biosciences, Lincoln, NE, U.S.A.) 1:1 with PBS-
0.1% Tween-20. Washed membranes were incubated for 1h at room temperature (RT) in OBB 1:1 
with PBS containing IRDye800CW-(1:20000)- or IRDye680-(1:30000)-conjugated secondary 
antibody (LI-COR®). Antibody-coated protein bands were visualized by Odyssey Infrared Imaging 
System Densitometry (LI-COR®). 
 
RNA extraction and q-PCR 
Cells (9x106) incubated in low oxygen or normoxia were washed with PBS and total RNA was 
extracted using Trizol reagent (#15596026; ThermoFisher Scientific) following the manufacturer’s 
protocol. Residual DNA was removed by DNase-I (#10104159001; Roche Diagnostics, Lewes, 
U.K.). RNA quality was evaluated in a 2% Agarose gel. cDNA was synthesized using ImProm-IITM 
Reverse Transcription System kit (#A3800; Promega, Madison, WI, U.S.A.) following 
manufacturer’s instructions. q-PCR was carried out using Green GoTaq qPCR Master Mix 
(#A6001; Promega). Primers were from Qiagen (CAIX, #QT00011697; HIF-1α, #QT00083664; 
Hilden, Germany) or designed as in Table S2.  
 
Culture Repopulation Ability (CRA) assay 
The CRA assay is an in vitro cognate of marrow repopulation ability assay in vivo36 where cells 
to be assayed are, rather than transplanted into syngeneic animals, transferred into growth-
permissive liquid cultures (LC2), to monitor the entity and kinetics of their repopulation.14,16,37 Peak 
value and time to peak of LC2 repopulation are indicators of stem cell potential of input cells. In this 
study, cells were subjected to drug treatment in liquid cultures (3x105 cells/ml) incubated in low-
oxygen (LC1) for 7 or 9 days, washed free of drug and transferred in fresh medium to normoxic 
LC2 (3x104 cells/ml), where viable cell number was determined at different times. Medium was 
never renewed during incubation in LC1 and LC2. 
 
Isolation of human mononuclear cells and CD34+ cell enrichment 
BM aspirates from CML patients or PB samples from healthy donors were obtained following 
informed consent and under the approval of the Ethics Committee of AOUC University Hospital 
(authorization n° 520/10, 18th october 2010, renewed with n° 2015/0032965, 4th november 2015). 
MC were Ficoll-isolated (Cedarlane Laboratories, Ontario, Canada) following manufacturer’s 
instructions, centrifuged and plated in cytokine-supplemented IMDM (Supplemental Methods). 
CD34+ cells were enriched from Ficoll-isolated PBMC or BMMC using CD34 Microbead Kit 
(#130-046-703, MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) following manufacturer’s 
protocol. The percentage of CD34+ cells was determined by flow cytometry. 
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Colony Formation Ability (CFA) assay 
CML patient-derived BMMC (2.5-5.0x104), or CD34-enriched PBMC from healthy donors (0.5-
1.0x103) were suspended in IMDM containing 2% FBS, 100 units/ml penicillin/streptomycin. Cells 
were plated in methyl-cellulose-containing medium (#04435, Stem Cell Technology, Vancouver, 
BC, Canada) in 35-mm dishes, treatments were applied at time 0 and colonies were counted after 
7, 14 or 21 days of incubation. Colony formation efficiency was calculated dividing the number of 
colonies scored by the number of cells plated. In some experiments, cells were serially replated 
after 7 or 14 days of culture.  
 
Long Term Culture-Initiating Cell (LTC-IC) assay 
BMMC from CML patients were drug-treated in low oxygen for 2 days, resuspended in human 
long-term medium (HLTM, Myelocult #05100, Stem Cell Technology) supplemented with 
hydrocortisone (10-6M) and plated onto irradiated (8000 cGy) M2-10B4 cells in collagen-coated 35-
mm dishes. Half of medium was replaced weekly. After 5 weeks, cells were replated (5x104/35-mm 
dish) in methyl-cellulose-containing medium (#04435, Stem Cell Technology) and colonies scored 
after 14 days. 
 
Mice 
C57BL/6J-CD45.1 mice (The Jackson Laboratory, Bar Harbor, ME, U.S.A) were handled in 
accordance with protocols and regulations approved by the IACUC of University of Massachusetts 
Medical School. CML mice were treated daily with ACF (8 mg/kg) or PBS via intraperitoneal 
injection, for 10 days starting from day 7 after bone marrow transplantation.  
 
Murine CML model  
Retroviruses were prepared and CML induced in mice as previously described.38,39 The 
retroviral construct MSCV-BCR/ABL-IRES-GFP was used to generate high-titer, helper-free, 
replication-defective ecotropic viruses by transient transfection of 293T cells. Viral titer was 
evaluated by flow cytometry following infection of NIH/3T3 cells. Donor mice were injected with 5-
FU (200 mg/kg; #6627, Sigma-Aldrich) via tail vein and sacrificed after 4 days. BM cells were 
flushed out of femurs and tibiae, infected with the above viruses, counted and transplanted (5x105 
cells in 300 μl/mouse) into recipient mice pre-treated with 2 doses of 550-cGy gamma 2h apart 
from each other. 
 
Flow cytometry 
Apoptosis was quantified in K562 or KCL22 cells by annexin V-APC (#31490016; Immunotools; 
Friesoythe, Germany), following the manufacturer’s instructions. Murine BM or PB cells were 
incubated with red blood cell lysis buffer, washed, resuspended in PBS and antibody-labelled 
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(Supplemental Methods). 7AAD (#559925, BD Biosciences, San Jose, CA, U.S.A.) was added 
before flow cytometry with a FACSAria (BD; Franklin Lakes, NJ, U.S.A.). Results were analyzed 
using the FlowJo software (Ashland, OR, U.S.A.). 
 
Statistical analyses 
Statistical analysis for pairwise comparisons was performed using Student’s t test for paired 
samples (data following a normal distribution), while that for multiple comparisons was performed 
by ANOVA, when values followed normal distribution, or nonparametric tests, using GraphPad 
software (La Jolla, CA, U.S.A.). A p value less than 0.05 was considered statistical significant.  
  
For personal use only.on June 28, 2017. by guest  www.bloodjournal.orgFrom 
RESULTS 
 
Acriflavine reduces cell number, c-MYC expression and stem cell potential in CML cells. 
We evaluated the effects of CML cell incubation in low oxygen on HIF-1α expression and 
activity. We found that HIF-1α protein is expressed in primary and stabilized CML cells in normoxia 
(Figure 1A), as observed in other blood cancers.40 Nevertheless, in K562 or KCL22 cells, the 
expression of nuclear HIF-1α protein increased in low oxygen (Figure 1B). Hypoxia also increased 
HIF-1α activity, as indicated by the enhanced expression of carbonic anhydrase 9 (CAIX) and 
vascular-endothelial growth factor (VEGF), both encoded for by HIF-1α-targeted genes (Figure 
1C). To identify drugs suitable for HIF-1α targeting in CML cells, we tested two HIF inhibitors with 
different mechanism of action. ACF, but not YC1 (Figure 1D), at concentrations around IC50 
(Figure S1A), inhibited the increase of CAIX and VEGF mRNA induced by a 2-day incubation in 
low oxygen. ACF or YC1 did not reduce HIF-1α mRNA, in agreement with their mechanisms of 
action. These results suggested that the reduction of viable cell number determined by YC1 in low 
oxygen (Figure S1A,B) was due to effects different from the inhibition of transcriptional activity of 
HIF-1α. Thus, we decided to use ACF for further investigations. 
ACF treatment reduced the number of viable KCL22 or K562 cells in low oxygen (Figure 2A), an 
effect paralleled by the induction of apoptosis (Figure 2B,C). The anti-proliferative effect of ACF 
was supported by the fact that ACF suppressed the expression of c-MYC (Figure 2D), a proto-
oncogene important for cell cycle regulation and BCR/Abl-driven transformation.41,42 ACF inhibited 
c-MYC expression at the transcriptional (data not shown) and protein expression levels, exhibiting 
in the latter case higher efficiency than IM. We previously demonstrated that leukemia cell lines, 
including CML lines, are functionally heterogeneous and comprise cell subsets endowed with 
different stem/progenitor cell potential. Such a heterogeneity emerged following incubation in low 
oxygen.4,5,14 On this basis, using K562 and KCL22 cells, we tested the effects of ACF on the 
maintenance of CML stem cell potential in low oxygen (Figure 2E). Cells were drug-treated or not 
(PBS addition) from time 0 in primary cultures (LC1) in low oxygen and transferred on day 7 to 
drug-free secondary cultures (LC2) incubated in normoxia, to exploit their repopulation potential. 
LC2 repopulation was indeed used as a read-out of maintenance of stem cell potential in LC1. This 
assay is an in vitro cognate of the marrow repopulation assay (see M&M).16,36,37 It is worth noting 
here that around 1% of cells rescued from a 7-day incubation in low-oxygen LC1 is responsible for 
LC2 repopulation (data not shown). Untreated LC1 cells repopulated LC2 after a 7-10 day lag-
phase as previously reported.4,5 LC2 repopulation was abolished by ACF (Figure 2E). To exclude 
that the lack of LC2 repopulation was due to residual ACF from LC1, we measured the amount of 
ACF in LC2 culture medium by LC-MS/MS (Supplemental Methods). ACF concentration resulted 
81.3±4.6 nM (vs 5 μM at time 0 of LC1). Such a concentration was found unable to affect growth 
kinetics of K562 or KCL22 cells (Figure S2). 
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In contrast to ACF, YC1 was ineffective in preventing LC2 repopulation (Figure S1C), likely 
because of its inefficacy in inhibiting HIF-1α activity (Figure 1D). The effect of HIF-1α inhibition in 
abolishing LC2 repopulation was confirmed in K562 cells by shRNA (Figure 2F). Finally, the effects 
of ACF on the maintenance of stem cell potential in low-oxygen culture were tested under 
conditions likely to better mimic the in vivo scenario, where LSC are adapted to the low-oxygen 
stem cell niche before the beginning of drug treatment. Thus, ACF was administered to K562 or 
KCL22 cultures at day 6 of incubation in low oxygen, and cells were transferred to LC2 at day 9. 
ACF suppressed LC2 repopulation, indicating that a previous LSC adaptation to low oxygen did not 
reduce the drug’s effectiveness on stem cell potential (Figure 2G). We also determined in K562 
cells the effects of low oxygen and ACF treatment on stemness-related genes, such as NANOG, 
OCT4 and SOX2 (Figure S3). The expression of these genes was markedly increased in low 
oxygen43 and ACF treatment reduced this increase. Thus, low oxygen boosts stem cell potential, 
which is targeted by ACF. 
As TKi represent a consolidated standard for CML therapy, it was important to determine 
whether the combination with ACF could affect the action of IM negatively and vice versa (Figure 
3). K562 or KCL22 cells were incubated in low oxygen for 3 days in the absence or presence of 
ACF or IM or their combination. As expected, IM reduced the number of viable cells in culture. 
Interestingly, drug combination enhanced the effects of single-drug treatments (Figure 3A). 
Furthermore, cells incubated in low oxygen and treated as above were transferred to normoxic LC2 
on day 7. Despite its effect on cell bulk, IM did not affect LC2 repopulation (Figure 3B), as we 
previously reported,4,5 in keeping with the refractoriness of LSC to TKi.2,3,6 ACF completely 
suppressed LC2 repopulation, irrespectively of the presence or absence of IM (Figure 3B). Thus, 
ACF targets TKi-insensitive LSC while contributing to the debulking of disease. 
 
Acriflavine reduces colony formation ability and stem cell potential of primary CML cells. 
The effectiveness of ACF on primary CML cells was then tested and compared to that of TKi. 
ACF concentration-dependently inhibited CFA by primary human (Figures 4A and S4A) or murine 
(data not shown) CML cells. As expected, IM or Dasa also inhibited CFA. ACF was similarly active 
on CD34-enriched CML cells (CML #9). On CD34+ cells from normal healthy donors (NHD; Figure 
4A and S4A), the effects of ACF were, for NHD#2, not significant throughout the incubation, or for 
NHD#1, significant at day 14, but not 7 and 21. Furthermore, the effects of 0.5 uM ACF were never 
significant for NHD, differently from what obtained for CML patients. ACF was at least as effective 
as IM or Dasa in reducing the number of viable cells in low-oxygen LC1 (Figures 4B and S4B). 
ACF suppressed LC2 repopulation by CML cells selected in low-oxygen LC1 (Figures 4C and 
S4C), in keeping with what observed for CML cell lines. IM or Dasa, on the contrary, did not affect 
LC2 repopulation significantly (Figure 4C). Thus, the stem cell potential of patient-derived CML 
cells selected in low oxygen was sensitive to ACF and resistant to TKi. Moreover, ACF did not 
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affect LC2 repopulation by CD34+ NHD cells. Overall, these results point to a good therapeutic 
index of ACF. 
The effects of ACF in the inhibition of stem cell potential of primary CML cells were confirmed 
using serial CFA and LTC-IC assays. ACF, alone or in combination with IM, reduced replating 
efficiency in all patients. On the contrary, IM, in two out of three patients, not only did not reduce, 
but actually enhanced CFA starting from tertiary cultures (Figure 5A). In the highly stringent LTC-IC 
assay, ACF, differently from IM, was strongly effective (Figure 5B).  
 
Acriflavine reduces CML development and LSC maintenance in vivo. 
The effects of ACF were tested in vivo using mice transplanted with BCR/abl-transduced BM 
cells.21,38,39,44 CML mice were treated daily with ACF (8 mg/kg) or placebo for 10 days starting one 
week after transplantation. ACF treatment was well tolerated in non-manipulated healthy mice, 
even at concentrations higher than 8 mg/kg, as far as overall physical appearance, behavior and 
weight changes are concerned (data not shown). Splenomegaly, lung infiltrate with myeloid cells 
and WBC count in PB of CML mice were reduced in the ACF-treated when compared to the 
placebo-treated group (Figure 6A-C). FACS analysis of PB cells showed that ACF reduced the 
percentage of GFP+ (BCR/abl-expressing), but not GFP- (BCR/abl-negative) myeloid (Gr-1+) cells 
(Figure 6D). In BM of ACF-treated mice, viable cell number decreased significantly when 
compared to the placebo-treated group (Figure 7A). The reduction of GFP+ cell number under 
ACF treatment was significantly higher than that of GFP- cells (Figure 7B). Accordingly, the 
percentage of apoptotic cells increased among GFP+, but not GFP-, cells (Figure 7C). In the same 
experiments, we tested whether ACF affected LSC compartment. The CD34-/Lineage-/Sca-1+/c-
Kit+ (CD34-/LSK) cells subset was analyzed in particular, which in mice includes the long-term 
LSC (LT-LSC) subset capable to induce CML when transplanted.3 ACF markedly reduced 
percentage and number of GFP+/CD34-/LSK cells (Figure 7D). By contrast, the effect of ACF on 
GFP-/CD34-/LSK cells was not significant. Overall, the in vivo data indicated that ACF is active on 
CML cells, CD34-/LSC in particular, with negligible effects on non-CML cells. 
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DISCUSSION 
The development of new therapeutic strategies able to target TKi-insensitive LSC appears of 
extreme importance in view of CML eradication. Low oxygen is a condition frequently occurring in 
neoplastic cell masses, including leukemias,45 and in tissue sites where normal and neoplastic 
stem cells are preferentially hosted.16,46 Previous work of ours showed that LSC selected under low 
oxygen tension are TKi-insensitive4,5 and that HIF-1α-dependent signaling is relevant to LSC 
maintenance in CML.21 This established a rationale for HIF targeting as a possible strategy for 
CML treatment. A number of HIF inhibitors has been developed,31,32,47–50 including those targeting 
a specific step of HIF-1 signaling, such as dimerization, coactivator recruitment51,52 or DNA 
binding.53 Here, we showed that ACF, an inhibitor of HIF dimerization,22 is capable to suppress the 
maintenance of LSC in vitro and in vivo as well as to inhibit CML cell growth.  
That ACF targets LSC of CML was first demonstrated in vitro. ACF suppressed stem cell 
potential in low oxygen in two cell lines and primary cells from fifteen patients, including one in 
blast crisis, as determined by CRA, serial CFA and LTC-IC assays. Importantly, in the same 
experiments, IM or Dasa were unable to affect stem cell potential significantly (see below). ACF 
suppressed stem cell potential even when administered to cells long after the beginning of 
incubation in low oxygen. This is very important in view of the facts that, when patients receive 
treatments, LSC are already hosted within low-oxygen stem cell niches and that adaptation to low 
oxygen can protect cancer stem cells from drug treatments.15,54,55 Furthermore, in low oxygen, ACF 
significantly reduced the expression of the stemness-related genes NANOG, OCT4 and SOX2, in 
keeping with the inhibition of stem cell potential. As these genes seem to be under HIF-2α, rather 
than HIF-1α, transcriptional control,56,57 this effect of ACF is likely due to the fact that the drug is 
also capable of inhibiting HIF-2α.22  
LSC targeting by ACF was confirmed in vivo. Using a murine model of BCR/Abl-induced 
CML,21,38,44 we demonstrated that ACF markedly reduces the maintenance of the LSK cell subset 
containing LT-LSC (CD34-/LSK)3 in BM. Thus, ACF emerged as a possible therapeutic strategy to 
suppress LSC and thereby prevent CML relapse. ACF was also capable to reduce the overall CML 
burden in mice, as indicated by the less severe splenomegaly and the fewer leukemia cells in BM, 
PB and lungs. Thus, ACF targeted significantly not only LSC, but also less immature CML cell 
subsets. This is consistent with the marked reduction of cell bulk in ACF-treated primary or 
stabilized CML cell cultures.  
The ACF-induced growth inhibition may be mediated, at least in part, by the reduction of c-MYC 
expression observed. ACF could interfere with the complex crosstalk between HIF proteins and c-
MYC,58 which collaborate to reprogram tumor cell metabolism towards glycolysis and sustain 
survival of oxygen-deprived cells.59 In CML, besides interacting with HIF proteins, c-MYC 
upregulates BCR/Abl expression,41,42 is necessary for BCR/Abl-induced transformation, increases 
genomic instability and participates in disease progression from chronic phase to blast crisis.60 
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Accordingly, in patients, an increase of c-MYC expression is related to a worse prognosis. The 
pharmacological inhibition of c-MYC has been reported to have an anti-leukemic effect which is 
synergistic with that of IM.61 Interestingly, in our experiments, ACF was more effective than IM in 
the reduction of c-MYC expression. It is worth pointing out that the inhibition of c-MYC by ACF may 
be also HIF-independent. Such a property, while detracting from the specificity of ACF effects on 
HIF, may turn out useful to increase the therapeutic activity of the drug.  
We previously showed that IM reduces CML cell bulk but does not affect the maintenance of 
stem cell potential in low oxygen.4,5 Here, we extended these findings, on one hand, to primary 
CML cells, on the other, to a second-generation TKi such as Dasa. These results are in agreement 
with the notion of the refractoriness to TKi, irrespective of TKi generation, exhibited by LSC2,3,6,17 
capable to stand low oxygen.4,5,16,46 Moreover, we confirmed that this refractoriness was not due to 
mutations of BCR/abl kinase domain, as the tested patients were negative for BCR/abl mutations. 
Finally, we observed that the combination of IM with ACF resulted more effective than either drug 
alone in reducing CML cell bulk in low oxygen and that IM did not interfere with the detrimental 
effect of ACF on stem cell potential or CFA. Both findings are of interest in view of a clinical use of 
the ACF/TKi combination. 
The translational projection of our work prompted us to test ACF on non-leukemic cells and 
mice. ACF did not inhibit significantly colony formation and stem cell potential by CD34+ PBMC 
from healthy donors. In the murine CML model, when we compared within individual mice 
(averaged) the effects of ACF on GFP+ (leukemic) cells with those on GFP- (non-leukemic) cells, 
we found that the latter were significantly less sensitive to ACF, as far as total PB or BM cells or 
CD34+/LSK are concerned. This is well in keeping with the less severe addiction to HIF-1α of HSC 
when compared to LSC.21 Finally, ACF was well tolerated by un-manipulated (non-BCR/abl-
transduced) mice even when administered at doses higher than that used for the experiments 
reported in this study (data not shown). This points to a good therapeutic index of ACF in 
discriminating leukemic from normal hematopoietic cells. 
On the basis of all above, ACF emerges as a good candidate to target at one time CML cell bulk 
and LSC, thus inducing remission and preventing late relapse of disease. It is worth noting that 
ACF is an already FDA-approved drug for non-oncological uses in humans,22 and that ACF was 
administered to patients for at least 5 months without major adverse effects.62 Thus, we propose 
ACF as a novel therapeutic approach to prevent CML relapse and, in combination with TKi, to 
enhance induction of remission. 
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FIGURE LEGENDS 
Figure 1. HIF-1α was expressed in CML cells and ACF inhibited the increase of HIF-1α target 
genes in low oxygen. (A) Primary (CML case #4) or CML cell lines were lysed and total cell 
lysates subjected to immuno-blotting with the indicated antibodies. GAPDH expression was used 
as a loading control. Migration of molecular weight markers is indicated on the left (kDa). One 
representative experiment out of 3 is shown. (B, C) Cells were incubated at the indicated oxygen 
concentrations for 3 days. (B) Nuclear lysates were subjected to immuno-blotting with the indicated 
antibodies. Fibrillarin was used to verify the equalization of protein loading. Migration of molecular 
weight markers is indicated on the left (kDa).  One representative experiment out of 3 is shown. (C) 
Total cell lysates were subjected to immuno-blotting with the indicated antibodies. GAPDH was 
used to verify equalization of protein loading. Migration of molecular weight markers is indicated on 
the left (kDa). One representative experiment out of 3 is shown. (D) Cells were incubated for 2 
days at the indicated oxygen concentrations, in the presence of 5 µM ACF or 50 µM YC1, or their 
solvents (PBS or DMSO, respectively).  CAIX, VEGF or HIF-1α mRNA were measured by qPCR. 
Data were normalized with respect to β-actin and expressed as fold-change with respect to the 
values obtained for time 0 (t0) cells. Values represent mean ± S.D. of 3 independent experiments, 
each carried out in triplicate; vs t0: * p≤0.05, ** p≤0.01; vs 0.1% O2 (PBS or DMSO), # p≤0.05, ## 
p≤0.01; n.s., not significant. 
Figure 2. ACF induced apoptosis and suppressed c-MYC expression and stem cell potential 
in CML cells. Cells were treated with PBS or 5 µM ACF or 1 µM IM and incubated at 0.1% O2 for 
the indicated times (primary culture; LC1). (A) Viable cells were counted at the indicated times of 
LC1. Dashed line indicates the number of plated cells. Values represent mean ± S.D. of data 
obtained from 3 independent experiments, each carried out in triplicate; * p≤0.05, ** p≤0.01. (B) 
Total cell lysates were subjected to immuno-blotting with the indicated antibodies. GAPDH was 
used to verify equalization of protein loading. Migration of molecular weight markers is indicated on 
the left (kDa). One representative experiment out of 3 is shown. (C) Cells were stained with 
annexin V-APC and analyzed by flow cytometry. Values represent mean ± S.D. of data obtained 
from 3 independent experiments, each carried out in triplicate; * p≤0.05. (D) Total cell lysates were 
subjected to immuno-blotting with the indicated antibodies. GAPDH was used to verify equalization 
of protein loading. Migration of molecular weight markers is indicated on the left (kDa). One 
representative experiment and densitometric analysis of data from 4 independent experiments are 
shown; values represent mean ± S.D.; vs PBS: * p≤0.05, ** p≤0.01; vs IM: # p≤0.05. (E) Cells were 
transferred from day-7 LC1 to drug-free normoxic secondary cultures (LC2) to determine the 
maintenance of stem cell potential in LC1 via the counting of viable cells at the indicated times of 
incubation in LC2. Values represent mean ± S.D. of three independent experiments. (F) K562 cells 
stably transfected with shRNA against HIF-1α (shHIF-1α) or control shRNA were incubated in low-
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oxygen LC1 for 7 days and then transferred to normoxic LC2, to count viable cells at the indicated 
times of incubation in LC2. Values represent mean ± S.D. of 3 independent experiments. (F, inset) 
Cells from time-0 LC1 were lysed and subjected to immuno-blotting with the indicated antibodies. 
ERK1/2 was used to verify equalization of protein loading. Migration of molecular weight markers is 
indicated on the left (kDa). (G) Cells were treated with PBS or 5 µM ACF from day 6 to day 9 of 
incubation in low-oxygen LC1 and then transferred to drug-free normoxic LC2 to count viable cells. 
Data, relative to the peak of LC2 repopulation (day 21), are expressed as fraction of the value 
obtained for PBS. Values represent mean ± S.D. of data obtained from 4 independent 
experiments; * p≤0.05, ** p≤0.01. 
Figure 3. IM did not interfere with the ACF-driven suppression of stem cell potential. Cells 
were treated with PBS or 5 µM ACF or 1 µM IM, alone or in combination (ACF+IM), and incubated 
at 0.1% O2 (LC1). (A) Viable cells were counted at day 3 of LC1. Data are expressed as fraction of 
the value obtained for PBS. Values represent mean ± S.D. of data obtained from 3 independent 
experiments; vs PBS: * p≤0.01; vs ACF: # p≤0.05; vs IM: § p≤0.05. (B) Cells were transferred from 
day-7 LC1 to drug-free normoxic secondary cultures (LC2), to determine the maintenance of stem 
cell potential in LC1 via the counting of viable cells at the indicated times of incubation in LC2. 
Values represent mean ± S.D. of data obtained from 3 independent experiments.  
Figure 4. ACF impaired stem cell potential and reduced colony formation ability of primary 
CML cells, but not normal cells. (A) Total (left) or CD34-enriched (right) light-density BMMC from 
CML patients or CD34-enriched light-density PBMC from normal healthy donors (NHD; right) were 
plated in methylcellulose-containing medium and treated as indicated from time 0 of incubation 
(PBS, vehicle for ACF or IM; DMSO, vehicle for DASA). Colony number was scored after 7 days. 
Values represent mean ± S.D. of data obtained from experiments performed in duplicate; vs PBS: * 
p≤0.05, ** p≤0.01; vs DMSO: # p≤0.05, ## p≤0.01; n.s., not significant. (B, C) Light-density BMMC 
from 12 CML patients or light-density PBMC from normal healthy donors (NHD) were treated as 
indicated (PBS, vehicle for ACF or IM; DMSO, vehicle for DASA) and incubated at 0.1% O2 (LC1). 
(B) Viable cells from CML patients were counted at day 3 (n=10) or day 7 (n=12) of incubation in 
low oxygen. Values represent mean ± S.D.; * p≤0.05, ** p≤0.01. (C) Cells were transferred from 
day-7 LC1 to drug-free normoxic LC2 to determine the maintenance of stem cell potential in LC1 
via the counting of viable cells at the indicated times of incubation in LC2. Values represent results 
from single experiments or mean ± S.D. of data obtained in triplicate (CML #8). 
Figure 5. ACF impaired serial colony formation and long-term culture-initiation abilities of 
primary CML cells. (A) Light-density BMMC from CML patients were plated in methylcellulose-
containing medium (I) and treated as indicated from time 0 of incubation (PBS, vehicle for ACF or 
IM). After 7-14 days, colony number was scored and cells replated in secondary, tertiary or 
quaternary cultures (II, III, IV). Data are expressed as fraction of the value obtained for PBS-
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treated cultures. Values represent mean ± S.D. of data obtained from experiments performed in 
duplicate; vs PBS: * p≤0.05, ** p≤0.01, n.s., not significant; vs IM: # p≤0.05, ## p≤0.01; vs ACF: § 
p≤0.05, §§ p≤0.01. (B) Light-density BMMC from CML patients were treated as indicated, 
incubated at 0.1% O2 for 2 days and transferred to drug-free liquid cultures incubated at 21% O2. 
After 5 weeks, cells were replated in methylcellulose-containing medium and colony number was 
scored after 14 days. Data are expressed as fraction of the value obtained for PBS-treated 
cultures. Values represent mean ± S.D. of data obtained from experiments performed in duplicate; 
vs PBS: ** p≤0.01, n.s., not significant; ACF vs IM: ## p≤0.01. 
Figure 6. ACF reduced CML development in vivo. CML mice were treated daily for 10 days with 
ACF or placebo and sacrificed after one additional day. (A) Spleen weight; dotted line: non-CML 
mice. Data are mean ± S.D. of 8 mice per experimental variant; ** p≤0.01. (B) Hematoxylin-stained 
lung sections (40x magnification) from two representative mice per experimental variant (scale bar:  
25 µm). (C) Total PB white blood cells (WBC). Data are mean ± S.D. from 8 mice per experimental 
variant; ** p≤0.01. (D) Percentage of GFP+ (leukemic) or GFP- (non-leukemic) myeloid cells (Gr-
1+) in PB. Plots show data from one representative mouse per experimental variant. Means ± S.D. 
from 8 mice per experimental variant are reported inside the plots.  
Figure 7. ACF reduced CML development and decreased the number of long-term LSC in 
vivo. CML mice were treated daily for 10 days with ACF or placebo and sacrificed after one 
additional day. (A) Number of BM viable cells. (B) Relative number of GFP+ (leukemic) or GFP- 
(non-leukemic) cells in BM; data are expressed as fraction of the value obtained for placebo. (C) 
Apoptotic rate of GFP+ or GFP- BM cells. (D) Percentage (left) and relative number (right) of 
GFP+ or GFP-/LT-LSK cells in BM; data are expressed as fraction of the value obtained for 
placebo. (A-D) Values represent mean ± S.D. of data from 8 mice per experimental variant; ACF- 
vs PBS-treated mice * p≤0.05; ** p≤0.01; *** p≤0.001; ACF-treated mice, GFP- vs GFP+ cells: § 
p≤0.05, §§ p≤0.01; n.s., not significant. 
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